[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Acelyrin Inc (SLRN)

Acelyrin Inc (SLRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 229,166
  • Shares Outstanding, K 100,954
  • Annual Sales, $ 0 K
  • Annual Income, $ -248,230 K
  • EBIT $ -293 M
  • EBITDA $ -311 M
  • 60-Month Beta 1.07
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.56
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.69
  • Most Recent Earnings $-0.55 on 05/14/25
  • Next Earnings Date 08/12/25
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate $-0.71
  • Number of Estimates 1
  • High Estimate $-0.71
  • Low Estimate $-0.71
  • Prior Year $-0.86
  • Growth Rate Est. (year over year) +17.44%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.95 +16.23%
on 05/15/25
2.65 -14.50%
on 05/01/25
+0.07 (+3.18%)
since 04/17/25
3-Month
1.95 +16.23%
on 05/15/25
2.94 -22.79%
on 04/02/25
+0.10 (+4.61%)
since 02/20/25
52-Week
1.85 +23.04%
on 02/11/25
7.25 -68.69%
on 07/17/24
-2.03 (-47.21%)
since 05/20/24

Most Recent Stories

More News
ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

SLRN : 2.27 (+1.79%)
ALMS : 22.38 (-3.58%)
Alumis Stockholders Approve Merger with ACELYRIN

Alumis Stockholders Approve Merger with ACELYRIN...

SLRN : 2.27 (+1.79%)
ALMS : 22.38 (-3.58%)
Alumis Stockholders Approve Merger with ACELYRIN

SLRN : 2.27 (+1.79%)
ALMS : 22.38 (-3.58%)
ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

LOS ANGELES, May 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, Inc. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the...

SLRN : 2.27 (+1.79%)
ALMS : 22.38 (-3.58%)
Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis

ACELYRIN Urges Stockholders to Vote FOR the Proposed Transaction Today...

SLRN : 2.27 (+1.79%)
ALMS : 22.38 (-3.58%)
Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis

SLRN : 2.27 (+1.79%)
ALMS : 22.38 (-3.58%)
ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis

Special Meeting of stockholders to vote on the transaction scheduled for May 13, 2025 Reminds stockholders to vote today FOR the proposed merger LOS...

SLRN : 2.27 (+1.79%)
ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis

SLRN : 2.27 (+1.79%)
ALMS : 22.38 (-3.58%)
Alumis and ACELYRIN Announce Amended Merger Agreement

SLRN : 2.27 (+1.79%)
ALMS : 22.38 (-3.58%)
Alumis and ACELYRIN Announce Amended Merger Agreement

SLRN : 2.27 (+1.79%)
ALMS : 22.38 (-3.58%)

Business Summary

Acelyrin Inc. is a clinical biopharma company. It focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep. Acelyrin Inc. is based in Agoura Hills, California.

See More

Key Turning Points

3rd Resistance Point 2.51
2nd Resistance Point 2.44
1st Resistance Point 2.35
Last Price 2.27
1st Support Level 2.19
2nd Support Level 2.12
3rd Support Level 2.03

See More

52-Week High 7.25
Fibonacci 61.8% 5.19
Fibonacci 50% 4.55
Fibonacci 38.2% 3.91
Last Price 2.27
52-Week Low 1.85

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.